Business Wire

PA-KNOPP-BIOSCIENCES

7.3.2017 12:02:04 CET | Business Wire | Press release

Share
Knopp Biosciences Announces Publication of Eosinophil-Lowering Effects of Dexpramipexole in Multiple Clinical Trials

Knopp Biosciences LLC today announced the publication of results from multiple clinical trials demonstrating the eosinophil-lowering effects of dexpramipexole, a small molecule treatment in development for eosinophil-associated diseases.

Eosinophils are white blood cells associated with inflammation in numerous diseases, including hypereosinophilic syndromes (HES), eosinophilic asthma, and chronic rhinosinusitis with nasal polyps. Dexpramipexole is an orally available small molecule in development for the treatment of HES, with a Phase 2 trial in eosinophilic asthma also planned to begin in the second half of 2017.

“The totality of the evidence to date, across multiple clinical studies in multiple indications, demonstrates that dexpramipexole is a targeted eosinophil-lowering agent with eosinophil-lowering effects equal to or greater than monoclonal antibodies against interleukin-5 or its receptor,” said Michael Bozik, M.D., president and CEO of Knopp Biosciences. “These newly released data strengthen our plans to rapidly advance dexpramipexole as a novel non-steroidal, orally available treatment in both HES and eosinophilic asthma.”

In a poster presentation (abstract #202) to the 2017 American Academy of Allergy and Immunology (AAAAI) in Atlanta, Georgia, data were reported from a Knopp-sponsored multicenter study of dexpramipexole in chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilia. The Phase 2 trial was an open label study of dexpramipexole 300 mg/day in 16 CRSwNP subjects with baseline blood absolute eosinophil counts (AEC) ≥0.30x109 /L and polyp eosinophilia. Co-primary endpoints examined were change in AEC and change in total polyp score (TPS) from baseline to end of study. Change in nasal polyp eosinophil counts from baseline to end of study was an exploratory endpoint.

Baseline AEC was 0.525x109 /L. AEC at month 6 was 0.031x109 /L, a 94% reduction (p<0.001). In the 12 subjects with baseline and end-of-study polyp biopsies, polyp tissue eosinophilia was reduced from 234 eosinophils per high-powered field at baseline to 5 eosinophils per high-powered field at end of study, a 97% reduction (p=0.001). There was no significant reduction in TPS despite profound reductions in blood and nasal polyp eosinophils. Dexpramipexole was well tolerated with no drug-related serious adverse events. Five subjects elected to continue on a long-term extension study.

The magnitude of eosinophil lowering (>90%) by dexpramipexole further strengthen the rationale for its development in eosinophilic asthma, in which eosinophil lowering by anti-IL5 and anti-IL5Rα antibodies has been demonstrated to reduce exacerbations, as well as in other eosinophil-associated diseases.

Knopp also announced the publication of significant eosinophil-lowering effects of dexpramipexole in earlier Phase 2 and Phase 3 clinical trials in amyotrophic lateral sclerosis (ALS). The results were published in the journal Blood Cells, Molecules and Diseases . The article abstract is available at this link .

In the Phase 2 clinical trial, a double-blind, placebo-controlled, dose-ranging study of dexpramipexole in 102 ALS subjects, highly significant reductions from baseline in mean blood eosinophils were observed in the 150 mg/day (-69.9%, p  < 0.001) and 300 mg/day (-43.5%, p  < 0.001) dose groups, respectively, at month 3. The significant eosinophil-lowering effect of dexpramipexole 300 mg/day was confirmed in the Phase 3 clinical trial, a double-blind study of 942 ALS subjects randomized 1:1 to placebo or dexpramipexole 300 mg daily treatment for up to 18 months. At month 6, the change from baseline in blood eosinophil counts was − 69.1% in the dexpramipexole-treated group (p  < 0.001), an effect that persisted through the end of study.

As previously announced , dexpramipexole has also demonstrated significant eosinophil lowering and corticosteroid sparing in an open label trial in hypereosinophilic syndromes.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need in clearly defined patient populations. Our clinical-stage small molecule, dexpramipexole, will be entering late-stage clinical studies in hypereosinophilic syndromes and Phase 2 clinical studies in eosinophilic asthma. Our preclinical platform is directed to small molecule treatments for neonatal epileptic encephalopathy, a devastating brain disorder of infants caused by a rare mutation in the KCNQ2 gene. For more information, visit www.knoppbio.com .

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs for dexpramipexole. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that dexpramipexole will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Contact:

Knopp Biosciences LLC
Tom Petzinger, +1-412-488-1776
tom@knoppbio.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 11:05:00 CET | Press release

India’s sovereign space-technology fund leads the first close of the ongoing INR 200 crore (c. USD 21 million) round SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing

Al Shera’a, DEWA’s Headquarters, Wins First Place in the YeS Honor Awards at the COP31 International Sustainable Buildings Competition20.11.2026 10:16:00 CET | Press release

In a new achievement that underscores Dubai’s pioneering position in smart and sustainable buildings, Al Shera’a, the headquarters of Dubai Electricity and Water Authority (DEWA), has won the first place in the YeS Honor Award–Sustainable Design category, in the COP31 International Sustainable Buildings Competition. The award was launched by the COP31 Presidency with the support of the Global Alliance for Buildings and Construction, hosted by the United Nations Environment Programme, during COP31 in Antalya, Türkiye. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118255551/en/ HE Saeed Mohammed Al Tayer, MD&CEO of DEWA, received the award in the presence of HE Amna bint Abdullah Al Dahak, UAE Minister of Climate Change and Environment, from HE Hasan Suver, Deputy Minister of Environment, Urbanisation and Climate Change of the Republic of Türkiye, representing the COP31 Presidency. The competition attracted more than 1,000

teamLab Biovortex Kyoto to Open 'Teahouse in a Sea of Light' for Savoring Tea. On View from Friday, November 20. Artworks Including Tea in Spontaneous Order on View20.11.2026 07:00:00 CET | Press release

teamLab Biovortex Kyoto opens ‘Teahouse in a Sea of Light’ on Friday, November 20, 2026, where visitors can savor tea within the Sea of Solidified Light. Artworks exhibited in the teahouse, including Tea in Spontaneous Order, are now unveiled. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117922442/en/ Aged Coffee Tonic, Tea in Spontaneous Order, 2021- ©︎ teamLab *Shot in real space. No AI or CGI. *No Artificial Colors Teahouse in a Sea of Light A space for savoring tea within a sea of light. When a cup of tea is made, the artwork is born. The tea interacts with nearby tea and the sea of light, creating a time structure throughout the entire space of the artwork. Visitors drink part of this formed order itself. Coinciding with the opening of ‘Teahouse in a Sea of Light,’ Pocket Garden of Eternal Existence is newly unveiled at the museum's entrance gate. teamLab Biovortex Kyoto teamLab Biovortex Kyoto is teamLab's largest

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release

Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye